Status:
RECRUITING
Fear of Recurrence and Stopping Immunotherapy
Lead Sponsor:
University of Pittsburgh
Conditions:
Cognitive Behavioral Therapy
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and impr...
Detailed Description
The intervention will be delivered through telemedicine to reduce the patient-related barriers to treatment including cost, transportation, and being able to maintain appointments while managing the s...
Eligibility Criteria
Inclusion
- Age 21 years and older
- Fluent in English
- Diagnosis of cancer and history of treatment with immunotherapy
Exclusion
- Active suicidal ideation, delusions or hallucinations
Key Trial Info
Start Date :
August 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04761328
Start Date
August 2 2021
End Date
December 31 2028
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Hillman Cancer Centers
Pittsburgh, Pennsylvania, United States, 15213